Responses to immune checkpoint inhibitors in nonagenarians

OncoImmunology

Volumn 5, Issue 11, 2016, Pages

  Johnpulle, Romany A N ^a   Conry, Robert M ^b   Sosman, Jeffrey A ^c   Puzanov, Igor ^d   Johnson, Douglas B ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Advanced melanoma; elderly; immunotherapy; ipilimumab; nivolumab; pembrolizumab

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PEMBROLIZUMAB;

AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EPISTAXIS; FEMALE; HUMAN; HUMAN TISSUE; LYMPHADENOPATHY; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84999007171     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1234572     Document Type: Article

References (39)

1. Tsai S, Balch C, Lange J. Epidemiology and treatment of melanoma in elderly patients. Nat Rev Clin Oncol 2010; 7(3):148-52; PMID:20142815; doi:10.1038/nrclinonc.2010.1
2. Geller AC, Miller DR, Annas GD, Demierre MF, Gilchrest BA, Koh HK. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002; 288(14):1719-20; PMID:12365954; doi:10.1001/jama.288.14.1719
3. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK. Annual Report to the Nation on the Status of Cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93(11):824-42; PMID:11390532; doi:10.1093/jnci/93.11.824
4. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351(10):998-1012; PMID:15342808; doi:10.1056/NEJMra041245
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-23; PMID:20525992; doi:10.1056/NEJMoa1003466
6. Berrocal A, Arance A, Lopez Martin JA, Soriano V, Muñoz E, Alonso L, Espinosa E, Lopez Criado P, Valdivia J, Martin Algarra S. Ipilimumab for advanced melanoma:experience from the Spanish expanded access program. Melanoma Res 2014; 24(6):577-83; PMID:25046550; doi:10.1097/CMR.0000000000000108
7. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33(17):1889-94; PMID:25667295; doi:10.1200/JCO.2014.56.2736
8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26):2443-54; PMID:22658127; doi:10.1056/NEJMoa1200690
9. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369(2):134-44; PMID:23724846; doi:10.1056/NEJMoa1305133
10. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma:a randomized dose-comparison cohort of a phase 1 trial. Lancet 2014; 384(9948):1109-17; PMID:25034862; doi:10.1016/S0140-6736(14)60958-2
11. Weber JS, Kudchadkar RR, Gibney GT, De Conti RC, Yu B, Wang W, Sarnaik A, Martinez AJ, Kroeger J, Eysmans C, et al. Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. J Clin Oncol 2013; 31(18):2233-365; ASCO Annual Meeting (suppl; abstr 9011)
12. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372(4):320-30; PMID:25399552; doi:10.1056/NEJMoa1412082
13. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr, Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4):375-84; PMID:25795410; doi:10.1016/S1470-2045(15)70076-8
14. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002):a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16(8):908-18; PMID:26115796; doi:10.1016/S1470-2045(15)00083-2
15. Postow MA, Luke JJ, Bluth MJ, Ramalya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013; 18(6):762-32; PMID:23716015; doi:10.1634/theoncologist.2012-0464
16. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129(7):1666-74; PMID:19131946; doi:10.1038/jid.2008.423
17. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA. Malignant melanoma in the elderly:different regional disease and poorer prognosis. J Cancer 2011; 2:538-43; PMID:22084644; doi:10.7150/jca.2.538
18. Chao C, Martin RCG, II, Ross MI, Reintgen DS, Edwards MJ, Noyes RD, Hagendoorn LJ, Stromberg AJ, McMasters KM. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004; 11(3):259-64; PMID:14993020; doi:10.1245/ASO.2004.04.015
19. Austin PF, Cruse CW, Lyman G, Schroer K, Glass F, Reintgen DS. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994; 1(6):487-94; PMID:7850555; doi:10.1007/BF02303614
20. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, et al. Prognostic factors analysis of 17,600 melanoma patients:validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19(16):3622-34; PMID:11504744
21. Cohen HJ, Cox E, Manton K, Woodbury M. Malignant melanoma in the elderly. J Clin Oncol 1987; 5(1):100-6; PMID:3806154
22. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC. Economic burden of melanoma in the elderly population:population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Arch Dermatol 2010; 146(3):249-56; PMID:20231494; doi:10.1001/archdermatol.2009.389
23. Denson AC, Mahipal A. Participation of the elderly population in clinical trials. Cancer Control 2014; 21(3):209-14; PMID:24955704
24. Shenoy P, Harugeri A. Elderly patients' participation in clinical trials. Perspect Clin Res 2015; 6(4):184-9; PMID:26623388; doi:10.4103/2229-3485.167099
25. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics:basic principles and practical applications. Br J Clin Pharmacol 2004; 57(1):6-14; PMID:14678335; doi:10.1046/j.1365-2125.2003.02007.x
26. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18(1):158-66; PMID:10623706
27. Ortiz CA, Goodwin JS, Freeman JL. The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med Sci Monit 2005; 11(5):163-72; PMID:15874907
28. Reyes Ortiz CA, Freeman JL, Kuo YF, Goodwin JS. The influence of marital status on stage at diagnosis and survival of older persons with melanoma. J Gerontol A Biol Sci Med Sci 2007; 62(8):892-8; PMID:17702882; doi:10.1093/gerona/62.8.892
29. Hegde UP, Chakraborty N, Mukherji B, Grant Kels JM. Metastatic melanoma in the older patient:immunologic insights and treatment outcomes. Expert Rev Pharmacoeconomics Outcomes Res 2011; 11(2):185-193; doi:10.1586/erp.11.14
30. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 2006; 106(6):1353-7; PMID:16475151; doi:10.1002/cncr.21748
31. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, et al. Anti-tumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005; 23(35):8968-77; PMID:16204013; doi:10.1200/JCO.2005.01.109
32. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33(17):1889-94; PMID:25667295; doi:10.1200/JCO.2014.56.2736
33. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26):2521-32; PMID:25891173; doi:10.1056/NEJMoa1503093
34. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schaderdorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1):23-34; PMID:26027431; doi:10.1056/NEJMoa1504030
35. McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanoma in the US. Cancer 2005; 103(5):1000-7; PMID:15651058; doi:10.1002/cncr.20866
36. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L. Ipilimumab-induced hypophysitis:a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99(11):4078-85; PMID:25078147; doi:10.1210/jc.2014-2306
37. Lutzky J, Wolchok J, Hamid O, Lebbe C, Pehamberger H, Linette G, de Pril V, Ibrahim R, Hoos A, O'Day S. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009; 27(15):2417-574(15s); ASCO Annual Meeting (suppl; abstr 9034); PMID:19075254
38. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treatment with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23(25):6043-6053; PMID:16087944; doi:10.1200/JCO.2005.06.205
39. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua M, Hwu W-J, Weber JS, Gangadhar TC, Joseph RW, et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol 2016; 34(18):533-2198; ASCO Annual Meeting (suppl; abstr 9503); PMID:26951310